<DOC>
	<DOC>NCT02629822</DOC>
	<brief_summary>The primary objectives of this study are to evaluate the antiretroviral activity and to evaluate the safety and tolerability of open-label MK-1439A consisting of a single fixed-dose combination (FDC) tablet of MK-1439 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg in treatment-naive HIV-1 infected participants with selected NNRTI transmitted resistance mutations.</brief_summary>
	<brief_title>Safety and Efficacy of MK-1439A in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)</brief_title>
	<detailed_description />
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Is HIV1 positive within 45 days prior to the treatment phase of this study, and have HIV treatment indicated based on physician assessment. Is naïve to antiretroviral therapy (ART) including investigational antiretroviral agents. Prior to screening, have had a genotype performed confirming the presence of only one of the following NNRTI mutations: K103N, Y181C, or G190A. Is considered clinically stable with no signs or symptoms of active infection at time of entry into the study (i.e. clinical status and all chronic medications should be unchanged for at least 2 weeks prior to the start of treatment in this study). Is highly unlikely to become pregnant or to impregnate a partner Is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence. Has been treated for a viral infection other than HIV1, such as hepatitis B, with an agent that is active against HIV1, including, but not limited to, adefovir, tenofovir, entecavir, emtricitabine, or lamivudine. Has documented or known resistance to study drugs (MK1439, lamivudine, and/or tenofovir) Has participated or anticipates participating in a study with an investigational compound/device within 30 days prior to signing informed consent Has any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids, tumor necrosis factor (TNF) antagonists, or other immunosuppressant drugs during the course of the trial. Requires or anticipates requiring any of the prohibited medications Has significant hypersensitivity or other contraindication to any of the components of the study drug Has a current (active) diagnosis of acute hepatitis due to any cause Has evidence of decompensated liver disease or has liver cirrhosis and a ChildPugh Class C score or PughTurcotte (CPT) score &gt; 9 Is pregnant, breastfeeding, or expecting to conceive Is female and expecting to donate eggs, or is male and is expecting to donate sperm at any time during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>